Humacyte, Inc. (HUMA)
Humacyte, Inc., engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
$0.66-0.02%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-71.0%
The outlook
Humacyte, Inc. currently reads as neutral based on buy — 1.6 avg of 5 analysts, below its 50- & 200-day averages, 5% of the way from its 52-week low to high, avg target +210% vs current price. This is a snapshot of current market data, not a forecast.
What’s behind the score
Analyst consensusBuy — 1.6 avg of 5 analysts
Price trendBelow its 50- & 200-day averages
52-week range5% of the way from its 52-week low to high
Price targetAvg target +210% vs current price
Analyst price target
~12-month · 5 analysts$2.05average target+210.1% vs now
Now $0.66
Low $1.00High $4.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$178.2M
52-wk high
$2.76
52-wk low
$0.55
50-day avg
$0.91
200-day avg
$1.06
Trailing P/E
—